What are the challenges in blinding participants and radiologists in trials evaluating imaging outcomes?

Official Title. A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered ... Sep 17, 2024 ... ... Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT ... The STAMPEDE2 trial is a phase III, randomized, ... Donepezil is an effective and safe drug for the long-term symptomatic treatment of mild to moderately severe AD for up to 144 weeks (2.8 years). Dec 1, 2023 ... Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug- ... Jun 7, 2021 ... To determine the efficacy of oral immunotherapy (OIT) with raw egg white powder and study its effects on humoral responses in children with persistent egg ... We describe two randomised trials where blinded outcome assessment was not possible, and discuss the strategies used to reduce the possibility of bias. Open-label studies lack the rigor of blinded studies. Since the lack of blinding can introduce significant bias, reserve the use of open-label studies for ... Jun 3, 2022 ... This open-label pilot study investigated whether practicing yoga in a class results in change in patients with alexisomia and alexithymia. Treating Foot Infections in Diabetic Patients: A Randomized, Multicenter, Open-Label Trial of Linezolid versus Ampicillin-Sulbactam/Amoxicillin-Clavulanate. A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease that causes inflammation of the membranes that ...